The end of the official shortage status for semaglutide came as telehealth company Hims & Hers which has been pushing sales of compounded semaglutide hard and lambasting the pharma industry for restricting access to GLP-1 drugs bought a peptide facility to raise its manufacturing capacity, sparking a sharp drop in its share price
And with growing data backing its supportive role in multiple physiological systems, it continues to gain popularity among proactive, self-aware health consumers
Particularly valuable for patients with compromised protein absorption, high training volumes, or those returning from injury who need accelerated tissue rebuilding
This product is supplied strictly as a research chemical / laboratory reagent for in-vitro and non-clinical laboratory research
FDA-approved GLP-1 and related incretin medications have product labels that describe contraindications, warnings, common adverse reactions, serious risks, and patient-counseling information